Abstract

Glutamatergic excitotoxicity is hypothesised to underlie synaptic loss in schizophrenia pathogenesis, but it is unknown whether synaptic markers are related to glutamatergic function in vivo. Additionally, it has been proposed that N-acetyl aspartate (NAA) levels reflect neuronal integrity. Here, we investigated whether synaptic vesicle glycoprotein 2 A (SV2A) levels are related to glutamatergic markers and NAA in healthy volunteers (HV) and schizophrenia patients (SCZ). Forty volunteers (SCZ n = 18, HV n = 22) underwent [11C]UCB-J positron emission tomography and proton magnetic resonance spectroscopy (1H-MRS) imaging in the left hippocampus and anterior cingulate cortex (ACC) to index [11C]UCB-J distribution volume ratio (DVR), and creatine-scaled glutamate (Glu/Cr), glutamate and glutamine (Glx/Cr) and NAA (NAA/Cr). In healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glu/Cr, in both the hippocampus and ACC. Furthermore, in healthy volunteers, but not patients, [11C]UCB-J DVR was significantly positively correlated with Glx/Cr, in both the hippocampus and ACC. There were no significant relationships between [11C]UCB-J DVR and NAA/Cr in the hippocampus or ACC in healthy volunteers or patients. Therefore, an appreciable proportion of the brain 1H-MRS glutamatergic signal is related to synaptic density in healthy volunteers. This relationship is not seen in schizophrenia, which, taken with lower synaptic marker levels, is consistent with lower levels of glutamatergic terminals and/or a lower proportion of glutamatergic relative to GABAergic terminals in the ACC in schizophrenia.

Details

Title
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study
Author
Onwordi Ellis Chika 1   VIAFID ORCID Logo  ; Whitehurst, Thomas 2   VIAFID ORCID Logo  ; Mansur Ayla 3 ; Statton Ben 4   VIAFID ORCID Logo  ; Berry Alaine 4 ; Quinlan, Marina 4 ; O’Regan Declan P 4   VIAFID ORCID Logo  ; Rogdaki, Maria 1   VIAFID ORCID Logo  ; Marques, Tiago Reis 5   VIAFID ORCID Logo  ; Rabiner Eugenii A 6   VIAFID ORCID Logo  ; Gunn, Roger N 3 ; Vernon, Anthony C 7   VIAFID ORCID Logo  ; Natesan Sridhar 8   VIAFID ORCID Logo  ; Howes, Oliver D 1   VIAFID ORCID Logo 

 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Faculty of Medicine, Imperial College London, Institute of Clinical Sciences (ICS), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839) 
 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Faculty of Medicine, Imperial College London, Institute of Clinical Sciences (ICS), London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111) 
 Hammersmith Hospital, Department of Brain Sciences, Imperial College London, The Commonwealth Building, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Invicro, Burlington Danes Building, London, UK (GRID:grid.498414.4) 
 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923) 
 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); South London and Maudsley NHS Foundation Trust, London, UK (GRID:grid.37640.36) (ISNI:0000 0000 9439 0839) 
 Invicro, Burlington Danes Building, London, UK (GRID:grid.498414.4); King’s College London, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
 King’s College London, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); King’s College London, MRC Centre for Neurodevelopmental Disorders, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
 Hammersmith Hospital Campus, MRC London Institute of Medical Sciences, Imperial College London, London, UK (GRID:grid.413629.b) (ISNI:0000 0001 0705 4923); Psychology and Neuroscience, King’s College London, Department of Psychosis Studies, Institute of Psychiatry, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
21583188
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2553124163
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.